NasdaqGM - Nasdaq Real Time Price USD

ANI Pharmaceuticals, Inc. (ANIP)

Compare
58.78 +0.48 (+0.82%)
At close: September 27 at 4:00 PM EDT
Loading Chart for ANIP
DELL
  • Previous Close 58.30
  • Open 58.58
  • Bid 58.75 x 100
  • Ask 58.91 x 100
  • Day's Range 58.00 - 59.08
  • 52 Week Range 48.20 - 70.81
  • Volume 184,636
  • Avg. Volume 345,080
  • Market Cap (intraday) 1.236B
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) 49.39
  • EPS (TTM) 1.19
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 82.40

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

www.anipharmaceuticals.com

642

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ANIP

View More

Performance Overview: ANIP

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ANIP
6.60%
S&P 500
20.30%

1-Year Return

ANIP
0.32%
S&P 500
34.27%

3-Year Return

ANIP
83.97%
S&P 500
28.79%

5-Year Return

ANIP
19.16%
S&P 500
92.71%

Compare To: ANIP

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ANIP

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    1.24B

  • Enterprise Value

    1.30B

  • Trailing P/E

    49.39

  • Forward P/E

    9.63

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.11

  • Price/Book (mrq)

    2.71

  • Enterprise Value/Revenue

    2.41

  • Enterprise Value/EBITDA

    11.13

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.01%

  • Return on Assets (ttm)

    3.38%

  • Return on Equity (ttm)

    5.90%

  • Revenue (ttm)

    538.95M

  • Net Income Avi to Common (ttm)

    22.93M

  • Diluted EPS (ttm)

    1.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    247.05M

  • Total Debt/Equity (mrq)

    60.32%

  • Levered Free Cash Flow (ttm)

    82.53M

Research Analysis: ANIP

View More

Company Insights: ANIP

Research Reports: ANIP

View More

People Also Watch